Get the Stockscreener App
79.66
3.48%
2.68
After Hours:
79.66
Tarsus Pharmaceuticals Inc stock is traded at $79.66, with a volume of 428.47K.
It is up +3.48% in the last 24 hours and up +12.48% over the past month.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
See More
Previous Close:
$76.98
Open:
$76.92
24h Volume:
428.47K
Relative Volume:
0.72
Market Cap:
$3.38B
Revenue:
$17.39M
Net Income/Loss:
$-135.89M
P/E Ratio:
-17.17
EPS:
-4.64
Net Cash Flow:
$-123.00M
1W Performance:
+9.24%
1M Performance:
+12.48%
6M Performance:
+84.44%
1Y Performance:
+71.68%
1-Day Range:
$73.86
$79.88
1-Week Range:
$72.80
$82.42
52-Week Range:
$38.51
$82.42
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
Name
Tarsus Pharmaceuticals Inc
Sector
Industry
Phone
(949) 409-9820
Address
15440 LAGUNA CANYON ROAD, IRVINE
Compare TARS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
79.66 | 3.27B | 17.39M | -135.89M | -123.00M | -4.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-25 | Initiated | Mizuho | Outperform |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-27-25 | Resumed | H.C. Wainwright | Buy |
| Nov-20-23 | Initiated | Goldman | Neutral |
| Jul-18-23 | Initiated | William Blair | Outperform |
| May-18-23 | Initiated | Guggenheim | Buy |
| Aug-01-22 | Initiated | Barclays | Overweight |
| Dec-21-21 | Initiated | H.C. Wainwright | Buy |
| Nov-23-21 | Initiated | Oppenheimer | Outperform |
| Nov-10-20 | Initiated | BofA Securities | Buy |
| Nov-10-20 | Initiated | Jefferies | Buy |
| Nov-10-20 | Initiated | Ladenburg Thalmann | Buy |
| Nov-10-20 | Initiated | Raymond James | Strong Buy |
View All
Tarsus Pharmaceuticals Inc Stock (TARS) Latest News
Will Tarsus Pharmaceuticals Inc. stock maintain dividend yieldMarket Trend Summary & Fast Gain Swing Alerts - newser.com
Tarsus Pharmaceuticals: Xdemvy Momentum Continues In Q3 (NASDAQ:TARS) - Seeking Alpha
Mizuho Initiates Coverage on Tarsus Pharmaceuticals (TARS) with Outperform Rating | TARS Stock News - GuruFocus
Mizuho initiates coverage on Tarsus Pharmaceuticals stock with Outperform rating - Investing.com Canada
Mizuho Initiates Tarsus Pharmaceuticals at Outperform With $100 Price Target - MarketScreener
Will Tarsus Pharmaceuticals Inc. stock remain a Wall Street favoriteWeekly Stock Recap & Daily Oversold Bounce Ideas - newser.com
Price-Driven Insight from (TARS) for Rule-Based Strategy - news.stocktradersdaily.com
Will Tarsus Pharmaceuticals Inc. stock outperform Nasdaq indexJuly 2025 Spike Watch & Growth Focused Stock Reports - newser.com
What catalysts could drive Tarsus Pharmaceuticals Inc. stock higherMarket Movement Recap & Daily Oversold Stock Bounce Ideas - newser.com
Is Tarsus Pharmaceuticals Inc. stock poised for growth2025 Stock Rankings & Daily Entry Point Trade Alerts - newser.com
Can Tarsus Pharmaceuticals Inc. stock resist market sell offs2025 Retail Activity & Real-Time Price Movement Reports - newser.com
Long term hold vs stop loss in Tarsus Pharmaceuticals Inc.Market Performance Summary & Fast Entry Momentum Alerts - newser.com
Midday Stock Roundup: Eledon Falls after Trial Report - Orange County Business Journal
Tarsus Pharmaceuticals stock hits all-time high at 76.85 USD By Investing.com - Investing.com Canada
Tarsus Pharmaceuticals stock hits all-time high at 76.85 USD - Investing.com
Full technical analysis of Tarsus Pharmaceuticals Inc. stockJuly 2025 Highlights & Low Risk Investment Opportunities - newser.com
Can Tarsus Pharmaceuticals Inc. stock sustain market leadershipJuly 2025 Reactions & Free Reliable Trade Execution Plans - newser.com
OC500 2025: BOBAK “BOBBY” AZAMIAN - Orange County Business Journal
What momentum indicators show for Tarsus Pharmaceuticals Inc. stockJuly 2025 Pullbacks & High Conviction Buy Zone Alerts - newser.com
Does Tarsus Pharmaceuticals Inc. fit your quant trading modelJuly 2025 News Drivers & Expert Verified Stock Movement Alerts - newser.com
Top chart patterns to watch in Tarsus Pharmaceuticals Inc.July 2025 Catalysts & Fast Gaining Stock Strategy Reports - newser.com
Tarsus Pharmaceuticals Inc Stock (TARS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):